This is a dose finding trial where participants will receive escalating doses of
acetazolamide, each for a 2-week dosing period followed by a 2-week washout period. The three
doses examined will be open-label 62.5mg twice daily, 125mg twice daily, and 250mg twice
daily of acetazolamide. A baseline Iohexol GFR measurement will be performed prior to the
first administration of each acetazolamide dose and then again following each dosing period.
Including a screening visit and a follow-up visit, there will be a total of 8 study visits
over approximately 16 weeks.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Diego
Collaborators:
JDRF The Leona M. and Harry B. Helmsley Charitable Trust